Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases - PubMed

Review

Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases

Uriel Katz et al. Curr Pharm Des. 2011.

Abstract

Intravenous Immunoglobulins (IVIg) are administered both as replacement therapy for certain immunodeficiencies and as immunomodulatory therapy for some autoimmune diseases. While the treatment with IVIg is approved in only a few autoimmune diseases, the number of off-label indications is increasing. The varied mechanisms by which IVIg attains its beneficial effect are diverse. There is much evidence for the beneficial and safety profile for IVIg in low as well as high-dose protocols. Patients prone to develop thrombotic events should be advised about the risk of IVIg therapy especially at high doses. This paper updates the mechanisms of action of IVIg as well as recent off-label indications.

Similar articles

• Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.

  Czernik A, Toosi S, Bystryn JC, Grando SA. Czernik A, et al. Autoimmunity. 2012 Feb;45(1):111-8. doi: 10.3109/08916934.2011.606452. Epub 2011 Sep 19. Autoimmunity. 2012. PMID: 21923613 Review.

• Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.

  Sapir T, Blank M, Shoenfeld Y. Sapir T, et al. Ann N Y Acad Sci. 2005 Jun;1051:743-78. doi: 10.1196/annals.1361.118. Ann N Y Acad Sci. 2005. PMID: 16127014 Review.

• High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.

  Rütter A, Luger TA. Rütter A, et al. J Am Acad Dermatol. 2001 Jun;44(6):1010-24. doi: 10.1067/mjd.2001.112325. J Am Acad Dermatol. 2001. PMID: 11369915 Review.

• [Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases].

  Mouthon L, Hurez V, Kazatchkine M. Mouthon L, et al. Ann Med Interne (Paris). 1993;144(8):506-13. Ann Med Interne (Paris). 1993. PMID: 8179238 Review. French.

• [Immunoglobulins and physiopathology: actual indications].

  Mouthon L, Guilpain P. Mouthon L, et al. Rev Med Interne. 2007 May;28 Spec No. 1:11-7. Rev Med Interne. 2007. PMID: 17768833 Review. French.

Cited by

• New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.

  Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. Ameratunga R, et al. Clin Exp Immunol. 2013 Nov;174(2):203-11. doi: 10.1111/cei.12178. Clin Exp Immunol. 2013. PMID: 23859429 Free PMC article. Review.

• Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies.

  Oaks M, Taylor S, Shaffer J. Oaks M, et al. Oncoimmunology. 2013 Jun 1;2(6):e24841. doi: 10.4161/onci.24841. Epub 2013 May 7. Oncoimmunology. 2013. PMID: 23894724 Free PMC article.

• Antibodies and Immunity During Kawasaki Disease.

  Hicar MD. Hicar MD. Front Cardiovasc Med. 2020 May 28;7:94. doi: 10.3389/fcvm.2020.00094. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 32671098 Free PMC article. Review.

• B Cells and Antibodies in Kawasaki Disease.

  Lindquist ME, Hicar MD. Lindquist ME, et al. Int J Mol Sci. 2019 Apr 13;20(8):1834. doi: 10.3390/ijms20081834. Int J Mol Sci. 2019. PMID: 31013925 Free PMC article. Review.

• Blood-derived product therapies for SARS-CoV-2 infection and long COVID.

  Wu J, Yang H, Yu D, Yang X. Wu J, et al. MedComm (2020). 2023 Nov 15;4(6):e426. doi: 10.1002/mco2.426. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 38020714 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Bentham Science Publishers Ltd.
  • Ingenta plc

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information